ACADIA Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Inc is an American biopharmaceutical company with its headquarters in San Diego, California. Operating internationally, the firm is engaged in the development of various treatments aimed at patients with Parkinson’s Disease, dementia, schizophrenia, and Rett syndrome. The firm was founded in 1993 as Receptor Technologies and was renamed as Acadia Pharmaceuticals in 1997.

Acadia was responsible for the development and commercialisation of the first FDA-approved therapy for patients suffering from hallucinations and delusions associated with Parkinson’s disease. The firm is also involved in late-stage development of treatments for psychosis associated with dementia and the debilitating symptoms of schizophrenia and Rett syndrome. Some of the company’s early-stage research focuses on novel approaches to pain management and managing cognition and neuro psychiatric symptoms in patients with central nervous system disorders.

The firm works in partnership with various organisations, including Neuron Pharmaceuticals, which it works with on its Rett syndrome therapies, and the Warren Centre for Neuroscience Drug Discovery, which it works with on the development of therapies for patients with CNS disorders. The firm is listed on the NASDAQ under the ticker ACAD.

Keep up to date on the latest share price changes by adding ACAD stock to your eToro watchlist.